ebook Munafa Stock Market Course + Intraday & FNO calls  

       

Aclaris Therapeutics (ACRS) Technical (Analysis) Reports Aclaris Therapeutics ["Technical Analysis"] Reports -USA Stock Exchange MunafaSutra.com

Complete & easy to understand technical analysis of Aclaris Therapeutics (ACRS)

Technical Analysis Report for USA stock ACRS Aclaris Therapeutics. Dated: 09 Jul 2026 Updated Daily. Stock trades under Health Care Deals in Major Pharmaceuticals in USA stock exchange

If you are looking for Tomorrow's Movement Predictions for USA stock ACRS Aclaris Therapeutics then click here. or read Experts views on Aclaris Therapeutics or Forecast & share price targets of Aclaris Therapeutics

Aclaris Therapeutics Opened at 5.61 and Closed at: 5.70, which is 3.16% of previous session's close. It moved within a range of 5.54 and 5.85
The session was a Bullish session with an average volume of 1778039, which is 58.01% of previous session's volumes.

  • The stock has shown an up move, and its short term trend is also positive and in an uptrend.
  • The stock has shown an up move, and its mid term trend is also positive and in an uptrend.
  • The stock has shown an up move, and its long term trend is also positive and in an uptrend.

Support for tomorrow is 5.62 and resistance for tomorrow is 5.93
These support and resistance points are valid for the first 5-15 minutes charts

Above are simple pivot point calculations. For a list of much stronger support and resistance levels click here. These are way more stronger support and resistance levels, and mark trend reversals and are Support & Resistance levels recommended by experts.

Support for tomorrow's hourly charts is 5.54, 5.39 resistance for tomorrow's hourly charts is 5.85, 6.01

10 Day SMA for Aclaris Therapeutics (ACRS) is 5.35 and stock is trading above these levels. This is a good sign for its short term trend

20 Day SMA for Aclaris Therapeutics (ACRS) is 4.92 and the stock is trading above these levels. This is a good sign for its mid term trend

50 Day SMA for Aclaris Therapeutics (ACRS) is 4.73 and the stock is trading above these levels. This is a good sign for its mid to long term trend

100 Day SMA is 4.19 and the stock is trading above these levels. This is a good sign for its long term trend

200 Day SMA Aclaris Therapeutics is 3.46 and stock is trading above these levels. This is a good sign for its long term trend

20 DMA of Aclaris Therapeutics is at 4.92 and 200 DMA is at 3.46, while 50 DMA and 100 DMA are at 4.73 and 4.19 respectively

Aclaris Therapeutics (ACRS) moving average of 20 SMA is at 4.92 and 20 EMA is at 5.09

Aclaris Therapeutics (ACRS) moving average of 50 SMA is at 4.73 and 50 EMA is at 4.7

Aclaris Therapeutics (ACRS) moving average of 100 SMA is at 4.19 and 100 EMA is at 4.31

Aclaris Therapeutics (ACRS) moving average of 200 SMA is at 3.46 and 200 EMA is at 3.66

Aclaris Therapeutics has performed better than Teladoc Health in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Penumbra Inc in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Mckesson Corporation in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Brookdale Senior in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Verrica Pharmaceuticals in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Meridian Bioscience in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Trinity Biotech in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Sintx Technologies in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Endra Life in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Macrogenics Inc in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Madrigal Pharmaceuticals in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Gilead Sciences in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Fulgent Genetics in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Dexcom Inc in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Corbus Pharmaceuticals in short term. Holding Aclaris Therapeutics could be a better choice for now!

Aclaris Therapeutics has performed better than Corcept Therapeutics in short term. Holding Aclaris Therapeutics could be a better choice for now!

Akebia Therapeutics has performed better than Aclaris Therapeutics in short term. You could have earned much better returns by investing in Akebia Therapeutics, about 26.5% more returns!

Aclaris Therapeutics Technical analysis of indicators

Price action analysis of Aclaris Therapeutics (ACRS) based on a short term time period is definitely positive! This means that there is a strong uptrend in the stock for the given time period. Buyers are extremely bullish on the stock.

ADX buy sell signal for Aclaris Therapeutics stock for short term is BUY. Signal strength is Strong and stock is losing momentum.

MACD generated a BUY signal for Aclaris Therapeutics in short term and the buy signal is strong.

MACD line is moving upwards which means that SELL signal is weakening, and buying is picking up momentum.

Aclaris Therapeutics Stock is trading near its recent HIGHS, which reflects strong buying momentum in short term! Bulls are getting stronger in this stock.

Ichimoku cloud is of green color and prices are above the green cloud Prices appear to be moving up

CCI has generated a buy signal for Aclaris Therapeutics in short term and BUY signal is strong.

RSI is generating a BUY signal in short term and the buying is gaining momentum.

MRSI is in positive zone. This is a BUY zone

Stock of Aclaris Therapeutics is picking up buying momentum according to indicator.

Volume based indicators are showing selling momentum.

Volume Weighted Averaged Price (VWAP) for short term is 5.24 and Aclaris Therapeutics ACRS stock is trading above this level. This is a good sign for the stock and it could move higher. VWAP is rising upwards.

People seem to be coming out and selling the Aclaris Therapeutics ACRS stock. Volume based technical analysis of Aclaris Therapeutics ACRS stock is negative.

Aclaris Therapeutics Stock is giving positive returns over a short term period. Returns for a longer term period have been positive

Force Index is moving in a negative zone, which indicates selling momentum for short term... Selling momentum is getting weaker.

Tomorrow's Predictions

You should also read Tomorrow's Movement Predictions for USA stock ACRS Aclaris Therapeutics These predictions are based on various factors, are easy to understand, and upto 75% accurate!

And ACRS Experts View which covers a lot of information including buying and selling signals

ACRS future forecast & share price targets

You can also take a look at the Charts and indicator analysis here Announcements & NEWS by Aclaris Therapeutics or View Candle Stick Charts here

Chart Aclaris Therapeutics (ACRS)  Technical (Analysis) Reports Aclaris Therapeutics [

Videos related to: Aclaris Therapeutics (ACRS) Technical (Analysis) Reports Aclaris Therapeutics ["Technical Analysis"] Reports -USA Stock Exchange MunafaSutra.com

Hindi Basics How To Trade In FnO Futures Options Stock Market

Hindi Video The Truth Of Stock Markets That Everyone Is Hiding From You

Aclaris Therapeutics (ACRS)  Technical (Analysis) Reports Aclaris Therapeutics [

 

Back to top